Androgen Receptor: A New Marker to Predict Pathological Complete Response in HER2-Positive Breast Cancer Patients Treated with Trastuzumab Plus Pertuzumab Neoadjuvant Therapy
(1) Background: Neoadjuvant therapy is the main therapeutic strategy for human epidermal growth factor receptor 2 (HER2)-positive breast cancer patients, and the combination of trastuzumab and pertuzumab (HP) has become a routine treatment. How to predict and screen patients who are less likely to r...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-02-01
|
| Series: | Journal of Personalized Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-4426/12/2/261 |
| _version_ | 1797478877016096768 |
|---|---|
| author | Jiayi Li Shuang Zhang Chen Ye Qian Liu Yuanjia Cheng Jingming Ye Yinhua Liu Xuening Duan Ling Xin Hong Zhang Ling Xu |
| author_facet | Jiayi Li Shuang Zhang Chen Ye Qian Liu Yuanjia Cheng Jingming Ye Yinhua Liu Xuening Duan Ling Xin Hong Zhang Ling Xu |
| author_sort | Jiayi Li |
| collection | DOAJ |
| description | (1) Background: Neoadjuvant therapy is the main therapeutic strategy for human epidermal growth factor receptor 2 (HER2)-positive breast cancer patients, and the combination of trastuzumab and pertuzumab (HP) has become a routine treatment. How to predict and screen patients who are less likely to respond to neoadjuvant therapy is the focus of research. The androgen receptor (AR) is a biomarker that is widely expressed in all breast cancer subtypes and is probably related to treatment response and prognosis. In this study, we investigated the relationship between AR expression and treatment response in HER2-positive breast cancer patients treated with HP neoadjuvant therapy. (2) Methods: We evaluated early breast cancer patients treated with HP neoadjuvant therapy from Jan. 2019 to Oct. 2020 at Peking University First Hospital Breast Cancer Center. The inclusion criteria were as follows: early HER2-positive breast cancer patients diagnosed by core needle biopsy who underwent both HP neoadjuvant therapy and surgery. We compared the clinical and pathological features between pathological complete response (pCR) and non-pCR patients. (3) Results: We included 44 patients. A total of 90.9% of patients received neoadjuvant therapy of taxanes, carboplatin, trastuzumab and pertuzumab (TCHP), and the total pCR rate was 50%. pCR was negatively related to estrogen receptor (ER) positivity (OR 0.075 [95% confidence interval (CI) 0.008–0.678], <i>p</i> = 0.021) and positively related to high expression levels of AR (OR 33.145 [95% CI 2.803–391.900], <i>p</i> = 0.005). We drew a receiver operating characteristic (ROC) curve to assess the predictive value of AR expression for pCR, and the area under the curve was 0.737 (95% CI 0.585–0.889, <i>p</i> = 0.007). The optimal cutoff of AR for predicting pCR was 85%. (4) Conclusion: AR is a potential marker for the prediction of pCR in HER2-positive breast cancer patients treated with HP neoadjuvant therapy. |
| first_indexed | 2024-03-09T21:37:50Z |
| format | Article |
| id | doaj.art-fc4c551740744dc6acb841b9a6ac09fa |
| institution | Directory Open Access Journal |
| issn | 2075-4426 |
| language | English |
| last_indexed | 2024-03-09T21:37:50Z |
| publishDate | 2022-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Personalized Medicine |
| spelling | doaj.art-fc4c551740744dc6acb841b9a6ac09fa2023-11-23T20:40:41ZengMDPI AGJournal of Personalized Medicine2075-44262022-02-0112226110.3390/jpm12020261Androgen Receptor: A New Marker to Predict Pathological Complete Response in HER2-Positive Breast Cancer Patients Treated with Trastuzumab Plus Pertuzumab Neoadjuvant TherapyJiayi Li0Shuang Zhang1Chen Ye2Qian Liu3Yuanjia Cheng4Jingming Ye5Yinhua Liu6Xuening Duan7Ling Xin8Hong Zhang9Ling Xu10Breast Disease Center, Peking University First Hospital, Beijing 100034, ChinaDepartment of Pathology, Peking University First Hospital, Beijing 100034, ChinaSchool of Public Health, Peking University Health Science Center, Haidian District, Beijing 100191, ChinaBreast Disease Center, Peking University First Hospital, Beijing 100034, ChinaBreast Disease Center, Peking University First Hospital, Beijing 100034, ChinaBreast Disease Center, Peking University First Hospital, Beijing 100034, ChinaBreast Disease Center, Peking University First Hospital, Beijing 100034, ChinaBreast Disease Center, Peking University First Hospital, Beijing 100034, ChinaBreast Disease Center, Peking University First Hospital, Beijing 100034, ChinaDepartment of Pathology, Peking University First Hospital, Beijing 100034, ChinaBreast Disease Center, Peking University First Hospital, Beijing 100034, China(1) Background: Neoadjuvant therapy is the main therapeutic strategy for human epidermal growth factor receptor 2 (HER2)-positive breast cancer patients, and the combination of trastuzumab and pertuzumab (HP) has become a routine treatment. How to predict and screen patients who are less likely to respond to neoadjuvant therapy is the focus of research. The androgen receptor (AR) is a biomarker that is widely expressed in all breast cancer subtypes and is probably related to treatment response and prognosis. In this study, we investigated the relationship between AR expression and treatment response in HER2-positive breast cancer patients treated with HP neoadjuvant therapy. (2) Methods: We evaluated early breast cancer patients treated with HP neoadjuvant therapy from Jan. 2019 to Oct. 2020 at Peking University First Hospital Breast Cancer Center. The inclusion criteria were as follows: early HER2-positive breast cancer patients diagnosed by core needle biopsy who underwent both HP neoadjuvant therapy and surgery. We compared the clinical and pathological features between pathological complete response (pCR) and non-pCR patients. (3) Results: We included 44 patients. A total of 90.9% of patients received neoadjuvant therapy of taxanes, carboplatin, trastuzumab and pertuzumab (TCHP), and the total pCR rate was 50%. pCR was negatively related to estrogen receptor (ER) positivity (OR 0.075 [95% confidence interval (CI) 0.008–0.678], <i>p</i> = 0.021) and positively related to high expression levels of AR (OR 33.145 [95% CI 2.803–391.900], <i>p</i> = 0.005). We drew a receiver operating characteristic (ROC) curve to assess the predictive value of AR expression for pCR, and the area under the curve was 0.737 (95% CI 0.585–0.889, <i>p</i> = 0.007). The optimal cutoff of AR for predicting pCR was 85%. (4) Conclusion: AR is a potential marker for the prediction of pCR in HER2-positive breast cancer patients treated with HP neoadjuvant therapy.https://www.mdpi.com/2075-4426/12/2/261breast cancerandrogen receptortrastuzumabpertuzumabneoadjuvant therapypathologic complete response |
| spellingShingle | Jiayi Li Shuang Zhang Chen Ye Qian Liu Yuanjia Cheng Jingming Ye Yinhua Liu Xuening Duan Ling Xin Hong Zhang Ling Xu Androgen Receptor: A New Marker to Predict Pathological Complete Response in HER2-Positive Breast Cancer Patients Treated with Trastuzumab Plus Pertuzumab Neoadjuvant Therapy Journal of Personalized Medicine breast cancer androgen receptor trastuzumab pertuzumab neoadjuvant therapy pathologic complete response |
| title | Androgen Receptor: A New Marker to Predict Pathological Complete Response in HER2-Positive Breast Cancer Patients Treated with Trastuzumab Plus Pertuzumab Neoadjuvant Therapy |
| title_full | Androgen Receptor: A New Marker to Predict Pathological Complete Response in HER2-Positive Breast Cancer Patients Treated with Trastuzumab Plus Pertuzumab Neoadjuvant Therapy |
| title_fullStr | Androgen Receptor: A New Marker to Predict Pathological Complete Response in HER2-Positive Breast Cancer Patients Treated with Trastuzumab Plus Pertuzumab Neoadjuvant Therapy |
| title_full_unstemmed | Androgen Receptor: A New Marker to Predict Pathological Complete Response in HER2-Positive Breast Cancer Patients Treated with Trastuzumab Plus Pertuzumab Neoadjuvant Therapy |
| title_short | Androgen Receptor: A New Marker to Predict Pathological Complete Response in HER2-Positive Breast Cancer Patients Treated with Trastuzumab Plus Pertuzumab Neoadjuvant Therapy |
| title_sort | androgen receptor a new marker to predict pathological complete response in her2 positive breast cancer patients treated with trastuzumab plus pertuzumab neoadjuvant therapy |
| topic | breast cancer androgen receptor trastuzumab pertuzumab neoadjuvant therapy pathologic complete response |
| url | https://www.mdpi.com/2075-4426/12/2/261 |
| work_keys_str_mv | AT jiayili androgenreceptoranewmarkertopredictpathologicalcompleteresponseinher2positivebreastcancerpatientstreatedwithtrastuzumabpluspertuzumabneoadjuvanttherapy AT shuangzhang androgenreceptoranewmarkertopredictpathologicalcompleteresponseinher2positivebreastcancerpatientstreatedwithtrastuzumabpluspertuzumabneoadjuvanttherapy AT chenye androgenreceptoranewmarkertopredictpathologicalcompleteresponseinher2positivebreastcancerpatientstreatedwithtrastuzumabpluspertuzumabneoadjuvanttherapy AT qianliu androgenreceptoranewmarkertopredictpathologicalcompleteresponseinher2positivebreastcancerpatientstreatedwithtrastuzumabpluspertuzumabneoadjuvanttherapy AT yuanjiacheng androgenreceptoranewmarkertopredictpathologicalcompleteresponseinher2positivebreastcancerpatientstreatedwithtrastuzumabpluspertuzumabneoadjuvanttherapy AT jingmingye androgenreceptoranewmarkertopredictpathologicalcompleteresponseinher2positivebreastcancerpatientstreatedwithtrastuzumabpluspertuzumabneoadjuvanttherapy AT yinhualiu androgenreceptoranewmarkertopredictpathologicalcompleteresponseinher2positivebreastcancerpatientstreatedwithtrastuzumabpluspertuzumabneoadjuvanttherapy AT xueningduan androgenreceptoranewmarkertopredictpathologicalcompleteresponseinher2positivebreastcancerpatientstreatedwithtrastuzumabpluspertuzumabneoadjuvanttherapy AT lingxin androgenreceptoranewmarkertopredictpathologicalcompleteresponseinher2positivebreastcancerpatientstreatedwithtrastuzumabpluspertuzumabneoadjuvanttherapy AT hongzhang androgenreceptoranewmarkertopredictpathologicalcompleteresponseinher2positivebreastcancerpatientstreatedwithtrastuzumabpluspertuzumabneoadjuvanttherapy AT lingxu androgenreceptoranewmarkertopredictpathologicalcompleteresponseinher2positivebreastcancerpatientstreatedwithtrastuzumabpluspertuzumabneoadjuvanttherapy |